Navigation Links
Remitting in Medical Technology

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

... of Neurology, Cologne City Hospitals, Germany. As previously reported, ATL/TV1102 significantly reduced disease activity in patients with Relapsing remitting Multiple Sclerosis (RRMS) in a randomized, double-blind, placebo-controlled Phase II study designed to obtain evidence of ATL/TV1102's effectiveness i...

Genmab Announces Upcoming Ofatumumab Studies

... developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country. ...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...ishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009. "This patent represents an important component in the development of our intellectual property in peptide...

Genmab Reaches Milestone in Ofatumumab Collaboration

...mately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the treatment of relapsing remitting multiple sclerosis (RRMS). "Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for pati...

Isis Pharmaceuticals Conference Call Notice

... to view the release titled: Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102, a Novel Drug for the Treatment of Relapsing remitting Multiple Sclerosis Demonstrated Significant Reduction in Disease Activity To access this call via telephone Please call 1-877-548-7901 in the Un...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

...ioavailability and pharmacodynamic effects with PI-2301, provide further evidence that PI-2301 may replace Copaxone as first-line therapy in relapsing remitting multiple sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a pro...

Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis

...tium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been app...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...cumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Reb...ypically characterized by an initial relapsing and remitting phase where episodes of transient neurological com...itive and visual impairments. At onset, relapsing- remitting MS is the most common form of this disease. Abou...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

..., Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

..., Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on ...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

...ial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis (MS). In this one-year, 8-subject extension clinical trial of relapsing remitting (RRMS) and secondary progressive (SPMS) subjects, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin therapy a...
Other Tags
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
(Date:7/10/2014)... cheeses and cakes that are just as tempting ... shelves, thanks to fresh insights into how proteins ... texture. , Funded by the Engineering and ... Heriot-Watt University and the University of Edinburgh has ... micro-particles and therefore closely mimic the behaviour of ...
(Date:7/9/2014)... 10, 2014) If you think winning is one of ... think again: Winning along with other mental bonuses ranked near ... falls into one of 11 big fun factors, according to ... all important when it comes to the "fun" factor, very ... what goes into this elusive conceptuntil now. , The results ...
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... had an aneurysm, she figured an invasive brain surgery and ... said Wakulich, who is 56 years old and lives in ... Then I met Dr. Bernard Bendok who told me about ... was something I didn,t even know was an option." , ... to evaluate the safety and effectiveness of the Microvention Inc. ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Urban Aboriginal people face unique health challenges 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2
Other Contents